AIM ImmunoTech to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Company to participate in live panel, “Pancreatic Cancer: Turning the Tide for One of the…
Company to participate in live panel, “Pancreatic Cancer: Turning the Tide for One of the…
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS…
Glen Rock, N.J., March 23, 2022 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or…
SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…
SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage company…
ARLINGTON, Mass., March 23, 2022 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical…
Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022…
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry…
-Frank Tufaro, Ph.D., appointed as Chief Operating Officer of Synthetic Biologics, transitioning from Chief Operating…
LONDON and PHOENIX, March 23, 2022 (GLOBE NEWSWIRE) — AccuStem Sciences, Inc. (OTC Pink: ACUT),…
MALVERN, Pa., March 23, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biotechnology company…
— Apraglutide, a next-generation GLP-2 analog, protected against chemotherapy-induced gastrointestinal (GI) damage and improved survival…
Results show the potential in the use of PLX-R18 for meaningful advantage over other existing…
The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability Results…
Compositions and Methods for Enhancing Anti-Viral Therapies CALGARY, Alberta, March 23, 2022 (GLOBE NEWSWIRE) —…
100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified…
Basel, 23 March 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the donation…
IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different solid tumor…
LONDON, March 23, 2022 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company”…
OVAL top-line data for ofra-vec progression free survival (PFS) primary endpoint expected in 2H 2022;…